Jaiswal A, Koley H, Ghosh A, Palit A, Sarkar B
10.1016/j.gendis.2019.01.002 256 XuY.ChenP.WangX.YaoJ.ZhuangS
Drug J-Code Missing or Incorrect: Prevent by verifying the HCPCS J-code for the specific drug administered and confirming the units billed reflect the actual dose
Interventions aimed at mitigating iron toxicity (e.g., chelation), selectively clearing pathological senescent cells or modulating their SASP (senotherapeutics), or directly inhibiting fibrotic pathways hold potential for developing more effective, non-hormonal treatments
Improves nerve function Help manage the symptoms of peripheral neuropathy Promote red blood cell production
More extensive preclinical and clinical studies, as well as randomized controlled trials, are also required to verify further the beneficial effect of targeting TMAO and its metabolic process, such as prebiotics and probiotics in AF patients